NKARTA INC. - COMMON STOCK

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

06 Jun 2025 05:52:00 By Nasdaq GlobeNewswire

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

14 May 2025 13:01:00 By Nasdaq GlobeNewswire

Nkarta to Participate in an April Investor Conference

01 Apr 2025 05:01:00 By Nasdaq GlobeNewswire

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

26 Mar 2025 13:01:00 By Nasdaq GlobeNewswire

Nkarta to Participate in March Investor Conferences

25 Feb 2025 05:01:00 By Nasdaq GlobeNewswire

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

05 Dec 2024 03:01:00 By Nasdaq GlobeNewswire

Nkarta to Participate in an Upcoming Investor Conference

26 Nov 2024 04:02:00 By Nasdaq GlobeNewswire

Nkarta to Participate in an Upcoming Investor Conference

12 Nov 2024 05:02:00 By Nasdaq GlobeNewswire

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

07 Nov 2024 13:02:00 By Nasdaq GlobeNewswire

Nkarta to Participate in Upcoming Investor Conference

03 Sep 2024 13:01:00 By Nasdaq GlobeNewswire

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

13 Aug 2024 18:03:42 By Nasdaq GlobeNewswire

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

13 Aug 2024 13:01:00 By Nasdaq GlobeNewswire

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

24 Jul 2024 03:00:00 By Nasdaq GlobeNewswire

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

16 Jul 2024 03:01:00 By Nasdaq GlobeNewswire

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications

27 Jun 2024 03:00:00 By Nasdaq GlobeNewswire

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

13 Jun 2024 13:01:00 By Nasdaq GlobeNewswire

Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

09 May 2024 13:01:00 By Nasdaq GlobeNewswire

Nkarta to Participate in Upcoming Investor Conferences

03 Apr 2024 13:02:00 By Nasdaq GlobeNewswire

Nkarta Announces Pricing of $240 Million Underwritten Offering

25 Mar 2024 03:30:00 By Nasdaq GlobeNewswire

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

21 Mar 2024 13:01:00 By Nasdaq GlobeNewswire